Skip to main content
Top
Published in: Gastric Cancer 4/2022

Open Access 11-06-2022 | Gastric Cancer | Review Article

Systematic review of health-related quality of life (HRQoL) issues associated with gastric cancer: capturing cross-cultural differences

Authors: Alison Rowsell, Samantha C. Sodergren, Vassilios Vassiliou, Anne-Sophie Darlington, Marianne G. Guren, Bilal Alkhaffaf, Chantelle Moorbey, Kristopher Dennis, Mitsumi Terada

Published in: Gastric Cancer | Issue 4/2022

Login to get access

Abstract

The treatment landscape for gastric cancer (GC) is constantly evolving with therapies affecting all aspects of health-related quality of life (HRQoL) which need careful monitoring. While there are HRQoL measures designed specifically to capture issues relevant to patients with GC, these might be outdated and only relevant to patients in westernised cultures. This review identifies the patient-reported measures used to assess HRQoL of patients with GC and compares the HRQoL measures used across cultures including East Asia, where GC is more prevalent. We conducted a systematic review of publications between January 2001 and January 2021. A total of 267 papers were identified; the majority (66%) of studies involved patients from East Asian countries. Out of the 24 HRQoL questionnaires captured, the European Organisation for Research and Treatment of Cancer Core Cancer measure (QLQ-C30) was the most widely used (60% of all studies and 62% of those involving patients from East Asian countries), followed by its gastric cancer-specific module (QLQ-STO22, 34% of all studies and 41% from East Asia). Eight questionnaires were developed within East Asian countries and, of the 20 studies including bespoke questions, 16 were from East Asia. There were six qualitative studies. HRQoL issues captured include diarrhoea, constipation, reflux, abdominal pain and abdominal fulness or bloating, difficulty swallowing, restricted eating, and weight loss. Psychosocial issues related to these problems were also assessed. Issues relating to the compatibility of some of the westernised measures within East Asian cultures were highlighted.
Literature
1.
go back to reference Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol. 2019;14(1):26–38.PubMed Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol. 2019;14(1):26–38.PubMed
2.
go back to reference Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(5):38–49.CrossRef Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(5):38–49.CrossRef
3.
go back to reference Al-Batran S-E, Homann N, Schmalenberg H, Kopp H-G, Haag GM, Luley KB, et al. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophagealjunction (GEJ) adenocarcinoma (FLOT4-AIO): a multicenter, randomized phase 3 trial. J Clin Oncol. 2017;35(15S):4004–4004.CrossRef Al-Batran S-E, Homann N, Schmalenberg H, Kopp H-G, Haag GM, Luley KB, et al. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophagealjunction (GEJ) adenocarcinoma (FLOT4-AIO): a multicenter, randomized phase 3 trial. J Clin Oncol. 2017;35(15S):4004–4004.CrossRef
4.
go back to reference Kataoka K, Dleersnijder A, Lordick F. Will molecular target agents enable the multidisciplinary treatment in stage IV gastric cancer? Eur J Surg Oncol. 2017;43(10):1835–45.PubMedCrossRef Kataoka K, Dleersnijder A, Lordick F. Will molecular target agents enable the multidisciplinary treatment in stage IV gastric cancer? Eur J Surg Oncol. 2017;43(10):1835–45.PubMedCrossRef
5.
go back to reference Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10111):2461–71.PubMedCrossRef Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10111):2461–71.PubMedCrossRef
6.
go back to reference Mitani S, Kadowaki S, Komori A, Kondoh C, Oze I, Kato K, et al. A phase II study of modified FOLFOX6 for advanced gastric cancer refractory to standard therapies. Adv Ther. 2020;37(6):2853–64.PubMedCrossRef Mitani S, Kadowaki S, Komori A, Kondoh C, Oze I, Kato K, et al. A phase II study of modified FOLFOX6 for advanced gastric cancer refractory to standard therapies. Adv Ther. 2020;37(6):2853–64.PubMedCrossRef
7.
go back to reference Wang J, Li Y, Qi Y. Effect of glutamine-enriched nutritional support on intestinal mucosal barrier function, MMP-2, MMP-9 and immune function in patients with advanced gastric cancer during perioperative chemotherapy. Oncol Lett. 2017;14(3):3606–10.PubMedPubMedCentralCrossRef Wang J, Li Y, Qi Y. Effect of glutamine-enriched nutritional support on intestinal mucosal barrier function, MMP-2, MMP-9 and immune function in patients with advanced gastric cancer during perioperative chemotherapy. Oncol Lett. 2017;14(3):3606–10.PubMedPubMedCentralCrossRef
8.
go back to reference Nunobe S, Hiki N. Function-preserving surgery for gastric cancer: current status and future perspectives. Transl Gastroenterol Hepatol. 2017;25(2):77.CrossRef Nunobe S, Hiki N. Function-preserving surgery for gastric cancer: current status and future perspectives. Transl Gastroenterol Hepatol. 2017;25(2):77.CrossRef
9.
go back to reference Chen W, Jiang X, Huang H, Ding Z, Li C. Jejunal pouch reconstruction after total gastrectomy is associated with better short-term absorption capacity and quality of life in early-stage gastric cancer patients. BMC Surg. 2018;18(1):63.PubMedPubMedCentralCrossRef Chen W, Jiang X, Huang H, Ding Z, Li C. Jejunal pouch reconstruction after total gastrectomy is associated with better short-term absorption capacity and quality of life in early-stage gastric cancer patients. BMC Surg. 2018;18(1):63.PubMedPubMedCentralCrossRef
10.
go back to reference Hong S, Park B, Noh H, Choi DJ. Herbal medicine for dumping syndrome: a systematic review and meta-analysis. Integr Cancer Ther. 2019;18:1–12.CrossRef Hong S, Park B, Noh H, Choi DJ. Herbal medicine for dumping syndrome: a systematic review and meta-analysis. Integr Cancer Ther. 2019;18:1–12.CrossRef
11.
go back to reference Scarpellini E, Arts J, Karamanolis G, Laurenius A, Siquini W, Suzuki H, Ukleja A, et al. International consensus on the diagnosis and management of dumping syndrome. Nat Rev Endocrinol. 2020;16(8):448–66.PubMedPubMedCentralCrossRef Scarpellini E, Arts J, Karamanolis G, Laurenius A, Siquini W, Suzuki H, Ukleja A, et al. International consensus on the diagnosis and management of dumping syndrome. Nat Rev Endocrinol. 2020;16(8):448–66.PubMedPubMedCentralCrossRef
12.
go back to reference McCall MD, Graham PJ, Bathe OF. Quality of life: a critical outcome for all surgical treatments of gastric cancer. World J Gastroenterol. 2016;22(3):1101–13.PubMedPubMedCentralCrossRef McCall MD, Graham PJ, Bathe OF. Quality of life: a critical outcome for all surgical treatments of gastric cancer. World J Gastroenterol. 2016;22(3):1101–13.PubMedPubMedCentralCrossRef
13.
go back to reference Pruthi DS, Ahmad M, Gupta M, Bansal S, Nautiyal V, Saini S. Assessment of quality of life in resectable gastric cancer patients undergoing chemoradiotherapy as adjuvant treatment. South Asian J Cancer. 2018;7(1):16–20.PubMedPubMedCentralCrossRef Pruthi DS, Ahmad M, Gupta M, Bansal S, Nautiyal V, Saini S. Assessment of quality of life in resectable gastric cancer patients undergoing chemoradiotherapy as adjuvant treatment. South Asian J Cancer. 2018;7(1):16–20.PubMedPubMedCentralCrossRef
14.
go back to reference Lee KW, Kim BJ, Kim MJ, Han HS, Kim JW, Park YI, Park SR. A multicenter randomized phase II study of docetaxel vs docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus either S-1 or capecitabine. Cancer Res Treat. 2017;49(3):706–16.PubMedCrossRef Lee KW, Kim BJ, Kim MJ, Han HS, Kim JW, Park YI, Park SR. A multicenter randomized phase II study of docetaxel vs docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus either S-1 or capecitabine. Cancer Res Treat. 2017;49(3):706–16.PubMedCrossRef
15.
go back to reference Zhang JK, Fang LL, Zhang DW, Jin Q, Wu XM, Liu JC, Zhang CD, Dai DQ. Type D personality in gastric cancer survivors: association with poor quality of life, overall survival, and mental health. J Pain Symptom Manag. 2016;52(1):81–91.CrossRef Zhang JK, Fang LL, Zhang DW, Jin Q, Wu XM, Liu JC, Zhang CD, Dai DQ. Type D personality in gastric cancer survivors: association with poor quality of life, overall survival, and mental health. J Pain Symptom Manag. 2016;52(1):81–91.CrossRef
16.
go back to reference Alkhaffaf B, Blazeby JM, Bruce IA, Morris RL. Patient priorities in relation to surgery for gastric cancer: qualitative interviews with gastric cancer surgery patients to inform the development of a core outcome set. BMJ Open. 2020;10(2):e034782.PubMedPubMedCentralCrossRef Alkhaffaf B, Blazeby JM, Bruce IA, Morris RL. Patient priorities in relation to surgery for gastric cancer: qualitative interviews with gastric cancer surgery patients to inform the development of a core outcome set. BMJ Open. 2020;10(2):e034782.PubMedPubMedCentralCrossRef
17.
go back to reference Alkhaffaf B, Metryka A, Blazeby JM, Glenny AM, Adeyeye A, Costa PM, Diez Del Val I, Gisbertz SS, Guner A, Law S, Lee HJ, Li Z, Nakada K, Reim D, Vorwald P, Baiocchi GL, Allum W, Chaudry MA, Griffiths EA, Williamson PR, Bruce IA. Core outcome set for surgical trials in gastric cancer (GASTROS study): international patient and healthcare professional consensus. Br J Surg. 2021;108(10):1216–24.CrossRef Alkhaffaf B, Metryka A, Blazeby JM, Glenny AM, Adeyeye A, Costa PM, Diez Del Val I, Gisbertz SS, Guner A, Law S, Lee HJ, Li Z, Nakada K, Reim D, Vorwald P, Baiocchi GL, Allum W, Chaudry MA, Griffiths EA, Williamson PR, Bruce IA. Core outcome set for surgical trials in gastric cancer (GASTROS study): international patient and healthcare professional consensus. Br J Surg. 2021;108(10):1216–24.CrossRef
19.
go back to reference Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.PubMedCrossRef Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.PubMedCrossRef
20.
go back to reference Rabin R, de Charro F. EQ-SD: a measure of health status from the EuroQol Group. Anna Med. 2001;33(5):337–43.CrossRef Rabin R, de Charro F. EQ-SD: a measure of health status from the EuroQol Group. Anna Med. 2001;33(5):337–43.CrossRef
21.
go back to reference Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570–9.PubMedCrossRef Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570–9.PubMedCrossRef
22.
go back to reference Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.PubMedCrossRef Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.PubMedCrossRef
23.
go back to reference Vickery CW, Blazeby JM, Conroy T, Arraras J, Sezer O, Koller M, Rosemeyer D, Johnson CD, Alderson D, EORTC Quality of Life Group. Development of an EORTC disease-specific quality of life module for use in patients with gastric cancer. Eur J Cancer. 2001;37(8):966–71.PubMedCrossRef Vickery CW, Blazeby JM, Conroy T, Arraras J, Sezer O, Koller M, Rosemeyer D, Johnson CD, Alderson D, EORTC Quality of Life Group. Development of an EORTC disease-specific quality of life module for use in patients with gastric cancer. Eur J Cancer. 2001;37(8):966–71.PubMedCrossRef
24.
go back to reference Blazeby JM, Conroy T, Bottomley A, Vickery C, Arraras J, Sezer O, Moore J, Koller M, Turhal NS, Stuart R, Van Cutsem E, D’haese S, Coens C, European Organisation for Research and Treatment of Cancer Gastrointestinal and Quality of Life Groups. Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO22, to assess quality of life in patients with gastric cancer. Eur J Cancer. 2004;40(15):2260–8.PubMedCrossRef Blazeby JM, Conroy T, Bottomley A, Vickery C, Arraras J, Sezer O, Moore J, Koller M, Turhal NS, Stuart R, Van Cutsem E, D’haese S, Coens C, European Organisation for Research and Treatment of Cancer Gastrointestinal and Quality of Life Groups. Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO22, to assess quality of life in patients with gastric cancer. Eur J Cancer. 2004;40(15):2260–8.PubMedCrossRef
25.
go back to reference Garland SN, Pelletier G, Lawe A, Biagioni BJ, Easaw J, Eliasziw M, et al. Prospective evaluation of the reliability, validity, and minimally important difference of the functional assessment of cancer therapy-gastric (FACT-Ga) quality-of-life instrument. Cancer. 2011;117(6):1302–12.PubMedCrossRef Garland SN, Pelletier G, Lawe A, Biagioni BJ, Easaw J, Eliasziw M, et al. Prospective evaluation of the reliability, validity, and minimally important difference of the functional assessment of cancer therapy-gastric (FACT-Ga) quality-of-life instrument. Cancer. 2011;117(6):1302–12.PubMedCrossRef
26.
go back to reference Eypasch E, Williams JI, Wood-Dauphinee S, Ure BM, Schmülling C, Neugebauer E, Troidl H. Gastrointestinal Quality of Life Index: development, validation and application of a new instrument. Br J Surg. 1995;82(2):216–22.PubMedCrossRef Eypasch E, Williams JI, Wood-Dauphinee S, Ure BM, Schmülling C, Neugebauer E, Troidl H. Gastrointestinal Quality of Life Index: development, validation and application of a new instrument. Br J Surg. 1995;82(2):216–22.PubMedCrossRef
27.
go back to reference Nakada K, Ikeda M, Takahashi M, Kinami S, Yoshida M, Uenosono Y, Kawashima Y, Oshio A, Suzukamo Y, Terashima M, Kodera Y. Characteristics and clinical relevance of postgastrectomy syndrome assessment scale (PGSAS)-45: newly developed integrated questionnaires for assessment of living status and quality of life in postgastrectomy patients. Gastric Cancer. 2015;18(1):147–58.PubMedCrossRef Nakada K, Ikeda M, Takahashi M, Kinami S, Yoshida M, Uenosono Y, Kawashima Y, Oshio A, Suzukamo Y, Terashima M, Kodera Y. Characteristics and clinical relevance of postgastrectomy syndrome assessment scale (PGSAS)-45: newly developed integrated questionnaires for assessment of living status and quality of life in postgastrectomy patients. Gastric Cancer. 2015;18(1):147–58.PubMedCrossRef
28.
go back to reference Meng Q, Wan CH, Luo JH, Tang XL, Li YF, Cun YL, Dai YG. Development of the system of quality of life instruments for cancer patients: stomach cancer (QLICP-ST). Ai Zheng. 2008;27(11):1212–6.PubMed Meng Q, Wan CH, Luo JH, Tang XL, Li YF, Cun YL, Dai YG. Development of the system of quality of life instruments for cancer patients: stomach cancer (QLICP-ST). Ai Zheng. 2008;27(11):1212–6.PubMed
29.
go back to reference Woo J, Lee JH, Shim KN, Jung HK, Lee HM, Lee HK. Does the difference of invasiveness between totally laparoscopic distal gastrectomy and laparoscopy-assisted distal gastrectomy lead to a difference in early surgical outcomes? A prospective randomized trial. Ann Surg Oncol. 2015;22(6):1836–43.PubMedCrossRef Woo J, Lee JH, Shim KN, Jung HK, Lee HM, Lee HK. Does the difference of invasiveness between totally laparoscopic distal gastrectomy and laparoscopy-assisted distal gastrectomy lead to a difference in early surgical outcomes? A prospective randomized trial. Ann Surg Oncol. 2015;22(6):1836–43.PubMedCrossRef
30.
go back to reference Morita S, Kaptein AA, Oba K, Sakamoto J. The domain structure of the EORTC QLQ-STO22 supported by Japanese validation data. Psychooncology. 2008;17(5):474–9.PubMedCrossRef Morita S, Kaptein AA, Oba K, Sakamoto J. The domain structure of the EORTC QLQ-STO22 supported by Japanese validation data. Psychooncology. 2008;17(5):474–9.PubMedCrossRef
31.
go back to reference Huang CC, Lien HH, Sung YC, Liu HT, Chie WC. Quality of life of patients with gastric cancer in Taiwan: validation and clinical application of the Taiwan Chinese version of the EORTC QLQ-C30 and EORTC QLQ-STO22. Psychooncology. 2007;16(10):945–9.PubMedCrossRef Huang CC, Lien HH, Sung YC, Liu HT, Chie WC. Quality of life of patients with gastric cancer in Taiwan: validation and clinical application of the Taiwan Chinese version of the EORTC QLQ-C30 and EORTC QLQ-STO22. Psychooncology. 2007;16(10):945–9.PubMedCrossRef
32.
go back to reference Oñate-Ocaña LF, Velázquez-Monroy N, Vázquez L, Espinosa-Mireles-de-Villafranca P, Núñez-Rosas E, Ovando-Lezama M, et al. Clinical validation of the EORTC QLQ-OG25 questionnaire for the evaluation of health-related quality of life in Mexican patients with esophagogastric cancers. Psychooncology. 2012;21(7):745–53.PubMedCrossRef Oñate-Ocaña LF, Velázquez-Monroy N, Vázquez L, Espinosa-Mireles-de-Villafranca P, Núñez-Rosas E, Ovando-Lezama M, et al. Clinical validation of the EORTC QLQ-OG25 questionnaire for the evaluation of health-related quality of life in Mexican patients with esophagogastric cancers. Psychooncology. 2012;21(7):745–53.PubMedCrossRef
33.
go back to reference Sadighi S, Mohagheghi MA, Montazeri A, Sadighi Z. Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF). BMC Cancer. 2006;6:274.PubMedPubMedCentralCrossRef Sadighi S, Mohagheghi MA, Montazeri A, Sadighi Z. Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF). BMC Cancer. 2006;6:274.PubMedPubMedCentralCrossRef
34.
go back to reference Dein S. Explanatory models of and attitudes towards cancer in different cultures. Lancet Oncol. 2004;5(2):119–24.PubMedCrossRef Dein S. Explanatory models of and attitudes towards cancer in different cultures. Lancet Oncol. 2004;5(2):119–24.PubMedCrossRef
35.
go back to reference Fischer MJ, Inoue K, Matsuda A, et al. Cross-cultural comparison of breast cancer patients’ Quality of Life in the Netherlands and Japan. Breast Cancer Res Treat. 2017;166(2):459–71.PubMedPubMedCentralCrossRef Fischer MJ, Inoue K, Matsuda A, et al. Cross-cultural comparison of breast cancer patients’ Quality of Life in the Netherlands and Japan. Breast Cancer Res Treat. 2017;166(2):459–71.PubMedPubMedCentralCrossRef
36.
go back to reference Gotay CC, Blaine D, Haynes SN, Holup J, Pagano IS. Assessment of quality of life in a multicultural cancer patient population. Psychol Assess. 2002;14(4):439–50.PubMedCrossRef Gotay CC, Blaine D, Haynes SN, Holup J, Pagano IS. Assessment of quality of life in a multicultural cancer patient population. Psychol Assess. 2002;14(4):439–50.PubMedCrossRef
37.
go back to reference Pagano IS, Gotay CC. Ethnic differential item functioning in the assessment of quality of life in cancer patients. Health Qual Life Outcomes. 2005;3:60.PubMedPubMedCentralCrossRef Pagano IS, Gotay CC. Ethnic differential item functioning in the assessment of quality of life in cancer patients. Health Qual Life Outcomes. 2005;3:60.PubMedPubMedCentralCrossRef
38.
go back to reference Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. BMJ. 2009;339:2535.CrossRef Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. BMJ. 2009;339:2535.CrossRef
39.
go back to reference Efficace F, Bottomley A, Osoba D, Gotay C, Flechtner H, D’haese S, Zurlo A. Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials–does HRQOL evaluation in prostate cancer research inform clinical decision making? J Clin Oncol. 2003;21(18):3502–11.PubMedCrossRef Efficace F, Bottomley A, Osoba D, Gotay C, Flechtner H, D’haese S, Zurlo A. Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials–does HRQOL evaluation in prostate cancer research inform clinical decision making? J Clin Oncol. 2003;21(18):3502–11.PubMedCrossRef
41.
go back to reference Carey S, Laws R, Ferrie S, Young J, Allman-Farinelli M. Struggling with food and eating–life after major upper gastrointestinal surgery. Support Care Cancer. 2013;21(10):2749–57.PubMedCrossRef Carey S, Laws R, Ferrie S, Young J, Allman-Farinelli M. Struggling with food and eating–life after major upper gastrointestinal surgery. Support Care Cancer. 2013;21(10):2749–57.PubMedCrossRef
42.
go back to reference Carrillo GM, Santamaría NP. Life after a gastrectomy: Experience of patients with gastric cancer. Enferm Clin (Engl Ed). 2019;29(1):27–33.CrossRef Carrillo GM, Santamaría NP. Life after a gastrectomy: Experience of patients with gastric cancer. Enferm Clin (Engl Ed). 2019;29(1):27–33.CrossRef
43.
go back to reference Ellis J, Brearley SG, Craven O, Molassiotis A. Understanding the symptom experience of patients with gastrointestinal cancers in the first year following diagnosis: findings from a qualitative longitudinal study. J Gastrointest Cancer. 2013;44(1):60–7.PubMedCrossRef Ellis J, Brearley SG, Craven O, Molassiotis A. Understanding the symptom experience of patients with gastrointestinal cancers in the first year following diagnosis: findings from a qualitative longitudinal study. J Gastrointest Cancer. 2013;44(1):60–7.PubMedCrossRef
44.
go back to reference Hofheinz R, Clouth J, Borchardt-Wagner J, Wagner U, Weidling E, Jen MH, Brück P. Patient preferences for palliative treatment of locally advanced or metastatic gastric cancer and adenocarcinoma of the gastroesophageal junction: a choice-based conjoint analysis study from Germany. BMC Cancer. 2016;16(1):937.PubMedPubMedCentralCrossRef Hofheinz R, Clouth J, Borchardt-Wagner J, Wagner U, Weidling E, Jen MH, Brück P. Patient preferences for palliative treatment of locally advanced or metastatic gastric cancer and adenocarcinoma of the gastroesophageal junction: a choice-based conjoint analysis study from Germany. BMC Cancer. 2016;16(1):937.PubMedPubMedCentralCrossRef
45.
go back to reference Eom BW, Lee J, Lee IS, Son YG, Ryu KW, Kim SG, KOrean QUality of life in Stomach cancer patients Study group (KOQUSS), et al. Development and validation of a symptom-focused quality of life questionnaire (KOQUSS-40) for gastric cancer patients after gastrectomy. Cancer Res Treat. 2021;53(3):763–72.PubMedCrossRef Eom BW, Lee J, Lee IS, Son YG, Ryu KW, Kim SG, KOrean QUality of life in Stomach cancer patients Study group (KOQUSS), et al. Development and validation of a symptom-focused quality of life questionnaire (KOQUSS-40) for gastric cancer patients after gastrectomy. Cancer Res Treat. 2021;53(3):763–72.PubMedCrossRef
46.
go back to reference Lagergren P, Fayers P, Conroy T, Stein HJ, Sezer O, Hardwick R, Hammerlid E, Bottomley A, Van Cutsem E, Blazeby JM, European Organisation for Research Treatment of Cancer Gastrointestinal and Quality of Life Groups. Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomach. Eur J Cancer. 2007;43(14):2066–73.PubMedCrossRef Lagergren P, Fayers P, Conroy T, Stein HJ, Sezer O, Hardwick R, Hammerlid E, Bottomley A, Van Cutsem E, Blazeby JM, European Organisation for Research Treatment of Cancer Gastrointestinal and Quality of Life Groups. Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomach. Eur J Cancer. 2007;43(14):2066–73.PubMedCrossRef
47.
go back to reference Blazeby JM, Conroy T, Hammerlid E, Fayers P, Sezer O, Koller M, et al. Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer. Eur J Cancer. 2003;39(10):1384–94.PubMedCrossRef Blazeby JM, Conroy T, Hammerlid E, Fayers P, Sezer O, Koller M, et al. Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer. Eur J Cancer. 2003;39(10):1384–94.PubMedCrossRef
48.
go back to reference Revicki DA, Wood M, Wiklund I, Crawley J. Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease. Qual Life Res. 1998;7(1):75–83.PubMedCrossRef Revicki DA, Wood M, Wiklund I, Crawley J. Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease. Qual Life Res. 1998;7(1):75–83.PubMedCrossRef
49.
go back to reference Rentz AM, Kahrilas P, Stanghellini V, Tack J, Talley NJ, de la Loge C, Trudeau E, Dubois D, Revicki DA. Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) in patients with upper gastrointestinal disorders. Qual Life Res. 2004;13(10):1737–49.PubMedCrossRef Rentz AM, Kahrilas P, Stanghellini V, Tack J, Talley NJ, de la Loge C, Trudeau E, Dubois D, Revicki DA. Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) in patients with upper gastrointestinal disorders. Qual Life Res. 2004;13(10):1737–49.PubMedCrossRef
50.
go back to reference Matsumoto T, Ohashi Y, Morita S, Kobayashi K, Shibuya M, Yamaji Y, Eguchi K, Fukuoka M, Nagao K, Nishiwaki Y, Niitani H, CPT-11 Lung Cancer Study Groups West and East. The quality of life questionnaire for cancer patients treated with anticancer drugs (QOL-ACD): validity and reliability in japanese patients with advanced non-small-cell lung cancer. Qual Life Res. 2002;11(5):483–93.PubMedCrossRef Matsumoto T, Ohashi Y, Morita S, Kobayashi K, Shibuya M, Yamaji Y, Eguchi K, Fukuoka M, Nagao K, Nishiwaki Y, Niitani H, CPT-11 Lung Cancer Study Groups West and East. The quality of life questionnaire for cancer patients treated with anticancer drugs (QOL-ACD): validity and reliability in japanese patients with advanced non-small-cell lung cancer. Qual Life Res. 2002;11(5):483–93.PubMedCrossRef
51.
go back to reference Martin AR, Pearson JD, Cai B, Elmer M, Horgan K, Lindley C. Assessing the impact of chemotherapy-induced nausea and vomiting on patients’ daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall. Support Care Cancer. 2003;11(8):522–7.PubMedCrossRef Martin AR, Pearson JD, Cai B, Elmer M, Horgan K, Lindley C. Assessing the impact of chemotherapy-induced nausea and vomiting on patients’ daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall. Support Care Cancer. 2003;11(8):522–7.PubMedCrossRef
52.
go back to reference Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage. 1997;13(2):63–74.PubMedCrossRef Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage. 1997;13(2):63–74.PubMedCrossRef
53.
go back to reference Ishigami S, Natsugoe S, Hokita S, Aoki T, Kashiwagi H, Hirakawa K, et al. Postoperative long-term evaluation of interposition reconstruction compared with Roux-en-Y after total gastrectomy in gastric cancer: prospective randomized controlled trial. Am J Surg. 2011;202(3):247–53.PubMedCrossRef Ishigami S, Natsugoe S, Hokita S, Aoki T, Kashiwagi H, Hirakawa K, et al. Postoperative long-term evaluation of interposition reconstruction compared with Roux-en-Y after total gastrectomy in gastric cancer: prospective randomized controlled trial. Am J Surg. 2011;202(3):247–53.PubMedCrossRef
54.
go back to reference Kawamura H, Takahashi N, Homma S, Minagawa N, Shibasaki S, Takahashi M, Taketomi A. Assessment of postoperative symptoms after laparoscopy-assisted distal gastrectomy for stage I gastric cancer. Int Surg. 2014;99(5):645–9.PubMedPubMedCentralCrossRef Kawamura H, Takahashi N, Homma S, Minagawa N, Shibasaki S, Takahashi M, Taketomi A. Assessment of postoperative symptoms after laparoscopy-assisted distal gastrectomy for stage I gastric cancer. Int Surg. 2014;99(5):645–9.PubMedPubMedCentralCrossRef
55.
go back to reference Hu X, Zhao F, Yu H, et al. GC-PROM: validation of a patient-reported outcomes measure for Chinese patients with gastric cancer. BMC Cancer. 2020;20:41.PubMedPubMedCentralCrossRef Hu X, Zhao F, Yu H, et al. GC-PROM: validation of a patient-reported outcomes measure for Chinese patients with gastric cancer. BMC Cancer. 2020;20:41.PubMedPubMedCentralCrossRef
56.
go back to reference Korenaga D, Orita H, Okuyama T, Moriguchi S, Maehara Y, Sugimachi K. Quality of life after gastrectomy in patients with carcinoma of the stomach. Br J Surg. 1992;79(3):248–50.PubMedCrossRef Korenaga D, Orita H, Okuyama T, Moriguchi S, Maehara Y, Sugimachi K. Quality of life after gastrectomy in patients with carcinoma of the stomach. Br J Surg. 1992;79(3):248–50.PubMedCrossRef
57.
go back to reference Wu CW, Hsieh MC, Lo SS, Lui WY, P’eng FK. Quality of life of patients with gastric adenocarcinoma after curative gastrectomy. World J Surg. 1997;21(7):777–82.PubMedCrossRef Wu CW, Hsieh MC, Lo SS, Lui WY, P’eng FK. Quality of life of patients with gastric adenocarcinoma after curative gastrectomy. World J Surg. 1997;21(7):777–82.PubMedCrossRef
58.
go back to reference Quan P, Zheng PY, You SF, Hua YQ, Song Y, Liu T, Wan CH, Lu JG. Clinical and psychometric validation of the quality of life assessment system for advanced gastric cancer based on traditional Chinese medicine. Chin J Integr Med. 2016;22(8):581–8.PubMedCrossRef Quan P, Zheng PY, You SF, Hua YQ, Song Y, Liu T, Wan CH, Lu JG. Clinical and psychometric validation of the quality of life assessment system for advanced gastric cancer based on traditional Chinese medicine. Chin J Integr Med. 2016;22(8):581–8.PubMedCrossRef
59.
go back to reference Chan Y, Ching JY, Cheung CM, Tsoi KK, Polder-Verkiel S, Pang SH, Quan WL, Kee KM, Chan FK, Sung JJ, Wu JC. Development and validation of a disease-specific quality of life questionnaire for gastro-oesophageal reflux disease: the GERD-QOL questionnaire. Aliment Pharmacol Ther. 2010;31(3):452–60.PubMedCrossRef Chan Y, Ching JY, Cheung CM, Tsoi KK, Polder-Verkiel S, Pang SH, Quan WL, Kee KM, Chan FK, Sung JJ, Wu JC. Development and validation of a disease-specific quality of life questionnaire for gastro-oesophageal reflux disease: the GERD-QOL questionnaire. Aliment Pharmacol Ther. 2010;31(3):452–60.PubMedCrossRef
60.
go back to reference Spitzer WO, Dobson AJ, Hall J, Chesterman E, Levi J, Shepherd R, Battista RN, Catchlove BR. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chronic Dis. 1981;34(12):585–97.PubMedCrossRef Spitzer WO, Dobson AJ, Hall J, Chesterman E, Levi J, Shepherd R, Battista RN, Catchlove BR. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chronic Dis. 1981;34(12):585–97.PubMedCrossRef
61.
go back to reference Sintonen H. The 15D instrument of health-related quality of life: properties and applications. Ann Med. 2001;33(5):328–36.PubMedCrossRef Sintonen H. The 15D instrument of health-related quality of life: properties and applications. Ann Med. 2001;33(5):328–36.PubMedCrossRef
62.
go back to reference The World Health Organization Quality of Life Assessment (WHOQOL): development and general psychometric properties. Soc Sci Med. 1998;46(12):1569–85. The World Health Organization Quality of Life Assessment (WHOQOL): development and general psychometric properties. Soc Sci Med. 1998;46(12):1569–85.
63.
go back to reference Ma YM, Ba CF, Wang YB. Analysis of factors affecting the life quality of the patients with late stomach cancer. J Clin Nurs. 2014;23(9–10):1257–62.PubMedCrossRef Ma YM, Ba CF, Wang YB. Analysis of factors affecting the life quality of the patients with late stomach cancer. J Clin Nurs. 2014;23(9–10):1257–62.PubMedCrossRef
64.
go back to reference Lee KE, Lim KH. Differences in factors affecting the quality of life over time after the gastrectomy in patients with stage I gastric Cancer. Gastroenterol Nurs. 2020;43(3):241–8.PubMedCrossRef Lee KE, Lim KH. Differences in factors affecting the quality of life over time after the gastrectomy in patients with stage I gastric Cancer. Gastroenterol Nurs. 2020;43(3):241–8.PubMedCrossRef
65.
go back to reference Maeda H, Sato M, Kobayashi M, Takiguchi N, Yoshikawa T, Yoshino S, Yoshida K, Tsuburaya A, Sakamoto J, Morita S. Validity of the Japanese version of functional assessment of cancer therapy-gastric (FACT-Ga) and its sensitivity to ascites volume change: a retrospective analysis of Japanese clinical trial participants. Support Care Cancer. 2016;24(11):4515–21.PubMedCrossRef Maeda H, Sato M, Kobayashi M, Takiguchi N, Yoshikawa T, Yoshino S, Yoshida K, Tsuburaya A, Sakamoto J, Morita S. Validity of the Japanese version of functional assessment of cancer therapy-gastric (FACT-Ga) and its sensitivity to ascites volume change: a retrospective analysis of Japanese clinical trial participants. Support Care Cancer. 2016;24(11):4515–21.PubMedCrossRef
66.
go back to reference Deng M, Lan Y, Luo S. Quality of life estimate in stomach, colon, and rectal cancer patients in a hospital in China. Tumour Biol. 2013;34(5):2809–15.PubMedCrossRef Deng M, Lan Y, Luo S. Quality of life estimate in stomach, colon, and rectal cancer patients in a hospital in China. Tumour Biol. 2013;34(5):2809–15.PubMedCrossRef
67.
go back to reference Sun DZ, Jiao JP, Zhang X, Xu JY, Ye M, Xiu LJ, et al. Therapeutic effect of Jinlongshe Granule () on quality of life of stage IV gastric cancer patients using EORTC QLQ-C30: a double-blind placebo-controlled clinical trial. Chin J Integr Med. 2015;21(8):579–86.PubMedCrossRef Sun DZ, Jiao JP, Zhang X, Xu JY, Ye M, Xiu LJ, et al. Therapeutic effect of Jinlongshe Granule () on quality of life of stage IV gastric cancer patients using EORTC QLQ-C30: a double-blind placebo-controlled clinical trial. Chin J Integr Med. 2015;21(8):579–86.PubMedCrossRef
68.
go back to reference Shu P, Tang H, Zhou B, Wang R, Xu Y, Shao J, Qi M, Xia Y, Huang W, Liu S. Effect of Yiqi Huayu Jiedu decoction on stages II and III gastric cancer: a multicenter, prospective, cohort study. Medicine (Baltimore). 2019;98(47): e17875.CrossRef Shu P, Tang H, Zhou B, Wang R, Xu Y, Shao J, Qi M, Xia Y, Huang W, Liu S. Effect of Yiqi Huayu Jiedu decoction on stages II and III gastric cancer: a multicenter, prospective, cohort study. Medicine (Baltimore). 2019;98(47): e17875.CrossRef
Metadata
Title
Systematic review of health-related quality of life (HRQoL) issues associated with gastric cancer: capturing cross-cultural differences
Authors
Alison Rowsell
Samantha C. Sodergren
Vassilios Vassiliou
Anne-Sophie Darlington
Marianne G. Guren
Bilal Alkhaffaf
Chantelle Moorbey
Kristopher Dennis
Mitsumi Terada
Publication date
11-06-2022
Publisher
Springer Nature Singapore
Published in
Gastric Cancer / Issue 4/2022
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-022-01309-6

Other articles of this Issue 4/2022

Gastric Cancer 4/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine